Dublin, Feb. 27, 2019 (GLOBE NEWSWIRE) -- The "2019 Future of Atrial Fibrillation R&D Pipeline Drugs and Companies- Analysis of Global Atrial Fibrillation Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments" report has been added to ResearchAndMarkets.com's offering.

The global demand for Atrial Fibrillation treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Atrial Fibrillation pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Atrial Fibrillation pipeline companies from advancing their products into Phase 3 or Phase 4.

Atrial Fibrillation Report Description

The H1-2019 pipeline review report on Atrial Fibrillation pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Atrial Fibrillation pipeline compounds.

The Atrial Fibrillation pipeline guide presents information on all active drugs currently being developed for Atrial Fibrillation. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Atrial Fibrillation pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Atrial Fibrillation drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Atrial Fibrillation product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Atrial Fibrillation pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Scope of Atrial Fibrillation pipeline report includes

  • An overview of Atrial Fibrillation disease including symptoms, causes, diagnosis and available treatment options is provided.
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise count of pipeline compounds
  • Company wise list of pipeline compounds
  • Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided

  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
  • Current status of development
  • Drug overview
  • Mechanism of Action
  • Pre-clinical and Clinical Trials

Reasons to Buy

  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Atrial Fibrillation pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Atrial Fibrillation pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into the market through in-depth strategic analysis review
  • Know the list of companies participating in global Atrial Fibrillation pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company

Key Topics Covered:

1. List of Tables & Figures

2. Global Atrial Fibrillation Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology

3. Executive Summary
3.1 Atrial Fibrillation Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Atrial Fibrillation pipeline, H1- 2019
3.5 Mechanism of Action wise Atrial Fibrillation Pipeline Candidates

4. Acesion Pharma Atrial Fibrillation Pipeline Details
4.1 Acesion Pharma Business Profile
4.2 Acesion Pharma Atrial Fibrillation Drug Details
4.2.1 Drug Snapshot Originator Collaborator/Co-Developer Route of Administration Orphan Drug/Fast Track/Special Designation Area Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5. Aetas Pharma Atrial Fibrillation Pipeline Details

6. Allosteros Therapeutics Inc Atrial Fibrillation Pipeline Details

7. AnaBios Corporation Atrial Fibrillation Pipeline Details

8. ARCA biopharma Inc Atrial Fibrillation Pipeline Details

9. Boston Pharmaceuticals Inc Atrial Fibrillation Pipeline Details

10. Correvio Pharma Corp. Atrial Fibrillation Pipeline Details

11. Daiichi Sankyo Co Ltd Atrial Fibrillation Pipeline Details

12. Dong-A Socio Holdings Co Ltd Atrial Fibrillation Pipeline Details

13. Edge Therapeutics Inc Atrial Fibrillation Pipeline Details

14. Espero BioPharma Inc Atrial Fibrillation Pipeline Details

15. G3 Pharmaceuticals Inc Atrial Fibrillation Pipeline Details

16. Gilead Sciences Inc Atrial Fibrillation Pipeline Details

17. HUYA Bioscience International Atrial Fibrillation Pipeline Details

18. InCarda Therapeutics Inc Atrial Fibrillation Pipeline Details

19. Merck & Co Inc Atrial Fibrillation Pipeline Details

20. N-Gene Research Laboratories Inc Atrial Fibrillation Pipeline Details

21. Nissan Chemical Industries Ltd Atrial Fibrillation Pipeline Details

22. OMEICOS Therapeutics GmbH Atrial Fibrillation Pipeline Details

23. The Geneva Biotech Center SA Atrial Fibrillation Pipeline Details

24. Verseon Corp Atrial Fibrillation Pipeline Details

20. Latest Atrial Fibrillation Drug Pipeline Developments, 2019

21. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/6gml55/global_atrial?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs , Clinical Trials